Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
Cell Reports. Medicine
|
October 8, 2025
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1
Jean-Luc Van Laethem, Karen Geboes, Ivan Borbath, et al.
The New England Journal of Medicine
|
July 25, 2008
Sorafenib in advanced hepatocellular carcinoma
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
March 5, 2023
Endoscopic Ultrasound-guided Radiofrequency Ablation Versus Surgical Resection for Treatment of Pancreatic Insulinoma
Stefano Francesco Crinò, Bertrand Napoleon, Antonio Facciorusso, et al.
The Lancet. Gastroenterology & Hepatology
|
August 6, 2021
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2022
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
Gontran Verset, Ivan Borbath, Mark Karwal, et al.
The Lancet. Oncology
|
November 28, 2012
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Armando Santoro, Lorenza Rimassa, Ivan Borbath, et al.
British Journal of Cancer
|
January 18, 2022
Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma
Ali Belkouz, Stijn Van Roessel, Marin Strijker, et al.
Neuroendocrinology
|
July 11, 2018
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours
Eric Raymond, Matthew H Kulke, Shukui Qin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle, Maeve Lowery, Rachna T Shroff, et al.
Journal of Neuroendocrinology
|
June 22, 2023
Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST
Louis de Mestier, Matthieu Resche-Rigon, Clarisse Dromain, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
Cell Reports. Medicine
|
October 8, 2025
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1
Jean-Luc Van Laethem, Karen Geboes, Ivan Borbath, et al.
The New England Journal of Medicine
|
July 25, 2008
Sorafenib in advanced hepatocellular carcinoma
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
March 5, 2023
Endoscopic Ultrasound-guided Radiofrequency Ablation Versus Surgical Resection for Treatment of Pancreatic Insulinoma
Stefano Francesco Crinò, Bertrand Napoleon, Antonio Facciorusso, et al.
The Lancet. Gastroenterology & Hepatology
|
August 6, 2021
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2022
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
Gontran Verset, Ivan Borbath, Mark Karwal, et al.
The Lancet. Oncology
|
November 28, 2012
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Armando Santoro, Lorenza Rimassa, Ivan Borbath, et al.
British Journal of Cancer
|
January 18, 2022
Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma
Ali Belkouz, Stijn Van Roessel, Marin Strijker, et al.
Neuroendocrinology
|
July 11, 2018
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours
Eric Raymond, Matthew H Kulke, Shukui Qin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle, Maeve Lowery, Rachna T Shroff, et al.
Journal of Neuroendocrinology
|
June 22, 2023
Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST
Louis de Mestier, Matthieu Resche-Rigon, Clarisse Dromain, et al.
Page
of 9